BioMedNewsBreaks

FridayJan 10, 2025 9:41 am

BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Announces Public Offering of Common Stock and Warrants

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company focused on advanced immunotherapies, announced plans to offer shares of its common stock and/or pre-funded warrants in a public offering. Ladenburg Thalmann & Co. Inc. is acting as the exclusive placement agent. The offering's size and terms depend on market conditions and are yet to be finalized. Proceeds will support working capital and general corporate purposes. The securities will be offered under an effective shelf registration statement filed with the SEC, and interested parties can access the preliminary prospectus and accompanying documents via the SEC website or through Ladenburg Thalmann's Prospectus…

Continue Reading

WednesdayJan 08, 2025 2:29 pm

BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Paves Cash Runway to Advance CNM-Au8(R) for ALS

Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”). The company recently secured a new $10 million debt facility, which enables the payoff of another higher interest rate loan and the finance of operations to generate additional data to support the new drug application of lead drug candidate CNM-Au8 for ALS. “We believe that the proceeds from this new debt facility, including an extended interest-only period, will allow Clene the cash…

Continue Reading

TuesdayJan 07, 2025 1:10 pm

BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Announces Streamlined Pathway to Advance Buntanetap for AD

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), today announced that the FDA has accepted an updated protocol for the pivotal Phase 3 AD study, which is slated to begin in January 2025. In October 2024, the FDA granted clearance for Annovis to proceed with the pivotal Phase 3 AD studies based on its Phase 2/3 data demonstrating cognitive improvement in early-stage AD patients. The original protocol design proposed two separate trials that are now integrated into a single 6/18-month trial under the…

Continue Reading

MondayJan 06, 2025 8:50 am

BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) to Engage Investors and Partners at Key January Conferences

Scinai Immunotherapeutics (NASDAQ: SCNI) a biopharmaceutical company focused on inflammation and immunology products and CDMO services, announced CEO Amir Reichman and Chairman Mark Germain will participate in several high-profile events in January 2025. They will attend the IATI Mini Mixiii Conference in Miami on January 9, followed by the JP Morgan HealthCare Conference and SIC Biotech Symposium in San Francisco from January 13-15. The executives plan to meet with investors, potential pharmaceutical partners, and prospective CDMO clients to advance collaborations and highlight Scinai's innovative NanoAbs and biologics services. To view the full press release, visit https://ibn.fm/fkDUg About Scinai Immunotherapeutics Ltd.…

Continue Reading

FridayJan 03, 2025 2:36 pm

BioMedNewsBreaks — Adageis Is Reshaping Patient Care Through AI-Centric Approach

Adageis, a forward-thinking healthcare technology company, is ramping up patient care through flexible AI-centric software solutions for systems and providers, including accountable care organizations (“ACOs”), clinically integrated networks (“CINs”) and independent physician associations (“IPAs”). With a unique proposition in the space, the company is actively improving healthcare delivery and increasing value-based care revenue by streamlining operations via its ProActive Care Platform. “Integrating AI and machine learning, this easy-to-use platform works with existing electronic health records (‘HER’) systems and fits the needs of all current healthcare platforms, whether operated by providers owning a single clinic or a multispecialty healthcare system,” reads…

Continue Reading

FridayDec 27, 2024 1:49 pm

BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Eyes Opportunities Beyond ‘Year of Significant Progress’

Annovis Bio (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, was featured in a recent article that discussed the company’s year-end investor webcast, where it provided stakeholders with a comprehensive overview of 2024 milestones and strategic initiatives for 2025. The webcast also highlighted financial developments, including the securing of a $50 million At-The-Market (“ATM”) offering and ongoing strategic efforts to raise additional funds to support clinical trial development and long-term growth. “2024 has been a year of significant progress for Annovis Bio, and we are excited about the opportunities ahead,” Dr. Maria Maccecchini, founder, president…

Continue Reading

ThursdayDec 26, 2024 3:44 pm

BioMedNewsBreaks — Why Adageis Is ‘One to Watch’

Adageis focuses on leveraging advanced technology to meet the growing demand for value-based care and quality incentives in the healthcare sector. “With a commitment to innovation and practical solutions, Adageis empowers clinics, healthcare centers, and care networks to implement its ProActive Care Platform without the need for expensive platform changes or extensive staff training,” reads a recent article. “This approach reduces barriers to adoption and helps healthcare organizations maximize their potential in an increasingly complex industry landscape.” To view the full article, visit https://ibn.fm/JUeJK About Adageis Adageis is a healthcare technology innovator focused on addressing inefficiencies in care delivery through AI…

Continue Reading

ThursdayDec 26, 2024 2:58 pm

BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Receives FDA Roadmap on Potential Accelerated Pathway for CNM-Au8(R)

Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”), recently received additional written guidance and a roadmap from the U.S. Food and Drug Administration’s (“FDA”) Division of Neurology 1 regarding a potential accelerated approval pathway for lead drug candidate CNM-Au8 in ALS. “The FDA guidance on a potential path to meet the regulatory standard for substantial evidence of effectiveness supporting accelerated approval came following an in-person Nov. 1 Type C meeting with…

Continue Reading

MondayDec 23, 2024 10:12 am

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) to Present at JP Morgan 2025 Annual Healthcare Conference

HeartBeam (NASDAQ: BEAT), a medical technology company revolutionizing cardiac care, announced its participation in the JP Morgan 2025 Annual Healthcare Conference, set for Jan. 13-16, 2025, in San Francisco. CEO Robert Eno and CFO Timothy Cruickshank will meet with investors and potential partners to discuss the recently FDA-cleared HeartBeam system, the first cable-free, credit card-sized ECG device designed for comprehensive arrhythmia assessment. Combining its patented high-fidelity ECG technology with AI-driven analysis, HeartBeam aims to provide a longitudinal view of cardiac health, transforming cardiovascular diagnostics and predictive care for millions of patients worldwide. To view the full press release, visit https://ibn.fm/hv8sI…

Continue Reading

FridayDec 20, 2024 3:12 pm

BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Committed to Ensuring Highest Standards in Continued Buntanetap Trials

Annovis Bio (NYSE: ANVS) is a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases. The company’s lead candidate, buntanetap, is an innovative drug that targets multiple pathways involved in neurodegenerative diseases by inhibiting the production of neurotoxic proteins that lead to the death of neurons, thereby slowing or stopping disease progression. A recent article highlights the company’s successful clinical trials and its receipt of FDA clearance to proceed with a pivotal phase 3 Alzheimer’s disease program for buntanetap, set to begin in early 2025. “Our priority is to bring a safe and effective treatment to patients, and we are…

Continue Reading